CN114129612A - Plant extract with function of reducing uric acid, product prepared from plant extract and application of plant extract - Google Patents
Plant extract with function of reducing uric acid, product prepared from plant extract and application of plant extract Download PDFInfo
- Publication number
- CN114129612A CN114129612A CN202111552263.XA CN202111552263A CN114129612A CN 114129612 A CN114129612 A CN 114129612A CN 202111552263 A CN202111552263 A CN 202111552263A CN 114129612 A CN114129612 A CN 114129612A
- Authority
- CN
- China
- Prior art keywords
- plant extract
- uric acid
- parts
- extraction
- function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000419 plant extract Substances 0.000 title claims abstract description 67
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 52
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 229940116269 uric acid Drugs 0.000 title claims abstract description 51
- 238000000605 extraction Methods 0.000 claims abstract description 48
- 241000219784 Sophora Species 0.000 claims abstract description 20
- 150000004676 glycans Chemical class 0.000 claims abstract description 19
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 19
- 239000005017 polysaccharide Substances 0.000 claims abstract description 19
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 13
- 229930003944 flavone Natural products 0.000 claims abstract description 13
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 13
- 235000011949 flavones Nutrition 0.000 claims abstract description 13
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 10
- 238000010438 heat treatment Methods 0.000 claims abstract description 10
- 229930003935 flavonoid Natural products 0.000 claims abstract description 6
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 6
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 6
- 238000010992 reflux Methods 0.000 claims abstract description 5
- 238000003809 water extraction Methods 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- 239000000314 lubricant Substances 0.000 claims description 13
- 239000000796 flavoring agent Substances 0.000 claims description 11
- 235000013355 food flavoring agent Nutrition 0.000 claims description 11
- 201000001431 Hyperuricemia Diseases 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000000853 adhesive Substances 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 3
- 238000009423 ventilation Methods 0.000 claims description 3
- 239000008280 blood Substances 0.000 abstract description 17
- 210000004369 blood Anatomy 0.000 abstract description 17
- 238000000034 method Methods 0.000 abstract description 14
- 239000000284 extract Substances 0.000 abstract description 10
- 238000001727 in vivo Methods 0.000 abstract description 6
- 238000002156 mixing Methods 0.000 abstract description 6
- 230000029142 excretion Effects 0.000 abstract description 5
- 201000005569 Gout Diseases 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 2
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 239000000047 product Substances 0.000 description 19
- 239000007788 liquid Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000012085 test solution Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 244000046101 Sophora japonica Species 0.000 description 5
- 235000010586 Sophora japonica Nutrition 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 241000628997 Flos Species 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 229940126673 western medicines Drugs 0.000 description 3
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- UICJJKVDQQWMAA-UHFFFAOYSA-N S(=O)(=O)(O)O.C1(CC=NC2=C1C1=CC3=CC=CC=C3C=C1C=C2)=O Chemical compound S(=O)(=O)(O)O.C1(CC=NC2=C1C1=CC3=CC=CC=C3C=C1C=C2)=O UICJJKVDQQWMAA-UHFFFAOYSA-N 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Abstract
The invention provides a plant extract with a function of reducing uric acid, a product prepared from the plant extract and an application of the plant extract, and belongs to the technical field of biology. The invention provides a plant extract with uric acid reducing function, which is prepared by mixing sophora flower and sophora flower bud, extracting by a water extraction heating reflux extraction method, and optimizing the process by taking the contents of flavone and polysaccharide as indexes. The extracted plant extract has the functions of reducing the concentration of blood uric acid and relieving gout, and the flavonoid component and the polysaccharide in the extract promote the excretion of uric acid in vivo and accelerate the metabolism of uric acid in vivo, so that the blood uric acid level in vivo is stable. And the extracted raw materials are homologous in medicine and food, so the plant extract has the characteristics of safety and no side effect and has higher market competitiveness.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a plant extract with a function of reducing uric acid, and a product prepared from the plant extract and an application of the plant extract.
Background
Hyperuricemia is caused by excessive production of uric acid and/or reduced excretion of uric acid in the body, and is a metabolic disease caused by the increase of uric acid in blood due to the metabolic disorder of purine substances in the human body, wherein the daily production amount and excretion amount of uric acid in the body are approximately equal, one third of the production amount is from food, two thirds of the production amount is self-synthesized in the body, the excretion route is that one third is excreted from the intestinal tract, and two thirds is excreted from the kidney. Any of the above routes, if problematic, will cause uric acid elevation. Uric acid rises, and it hinders the process of blood secretion of uric acid, so uric acid cannot be discharged. When uric acid is too high, crystallization and deposition of urate can cause acute arthritis, tophus and interstitial nephritis, and severe cases can cause joint deformity and dysfunction, often accompanied with uric acid urinary calculus.
With the improvement of the quality of life of the public and the change of dietary structure and dietary habits, patients with hyperuricemia increase year by year, and a few patients with gout increase in the past, so that the patients are common to middle-aged and elderly people, and the patients also have a trend of being younger, and become a common disease. At present, most of the medicines clinically used for treating hyperuricemia are western medicines, and although the western medicines have certain curative effects, the western medicines have more side effects, such as strong dependence, easy relapse of diseases after stopping taking the medicines, and high medicine cost, and bring great economic pressure to patients.
Disclosure of Invention
In view of the above, the present invention aims to provide a plant extract with a function of reducing uric acid, and a product and an application prepared from the plant extract, wherein the plant extract has characteristics of small side effect, simple preparation process, and convenience for market promotion.
The invention provides a plant extract with a function of reducing uric acid, which is prepared by the following steps:
extracting the mixture of sophora flower and sophora flower bud by a water extraction heating reflux extraction method to obtain a plant extract;
the mass ratio of the mixture to water is 1: (8-12);
the extraction times are 2-3 times; the time for each extraction is 1-2 h.
Preferably, the mass ratio of the mixture to the water is 1: (10-12); the time for each extraction was 1.5 h.
Preferably, the heating temperature is 95-100 ℃.
Preferably, the mass ratio of the sophora flower to the sophora flower bud is (0.5-1): (0.5 to 1).
Preferably, the plant extract is concentrated and dried to obtain a powdered plant extract.
Preferably, the active ingredients in the powdered plant extract comprise total flavonoids and polysaccharides;
the mass percentage content of the total flavone is 32-43 percent;
the mass percentage of the polysaccharide is 3.3% -4.1%.
The invention provides a product with a function of reducing uric acid, which comprises the following components in parts by mass: 90-110 parts of plant extract, 70-90 parts of flavoring agent, 15-25 parts of adhesive and 1.8-2.3 parts of lubricant.
Preferably, the plant extract comprises 100 parts of plant extract, 80 parts of flavoring agent, 20 parts of adhesive and 2 parts of lubricant.
Preferably, the flavoring agent comprises xylitol; the binder comprises starch; the lubricant comprises magnesium stearate.
The invention provides application of the plant extract in preparing a health-care product for relieving ventilation or a medicine for treating hyperuricemia.
The plant extract with the function of reducing uric acid provided by the invention is prepared by the following steps: and (3) extracting the mixture of the sophora flower and the sophora flower bud by adopting a water extraction heating reflux extraction method, wherein the material-water ratio is controlled to be 8-12 times, the extraction time is 1-2 hours, and the extraction times are 2-3 times, so that the plant extract rich in the total flavone and polysaccharide is obtained. The extracted plant extract has the functions of reducing the concentration of blood uric acid and relieving gout, and the flavonoid component and the polysaccharide in the extract have the functions of promoting in vivo uric acid excretion and accelerating the metabolism of uric acid in vivo, so that the blood uric acid level in vivo is stable, and a new idea is provided for the treatment of hyperuricemia.
Meanwhile, the plant extract provided by the invention takes sophora japonica and sophora japonica as raw materials, the raw materials are wide and easy to obtain, the preparation process is simple and easy to obtain, the plant extract has the characteristic of low production cost, the raw materials belong to medicinal and edible medicinal materials, the plant extract has the characteristic of small side effect, can be widely applied to the preparation of health-care products and medicines, and has strong market competitiveness.
Detailed Description
The invention provides a plant extract with a function of reducing uric acid, which is prepared by the following steps: extracting the mixture of sophora flower and sophora flower bud by a water extraction heating reflux extraction method to obtain a plant extract; the mass ratio of the mixture to water is 1: (8-12); the extraction times are 2-3 times; the time for each extraction is 1-2 h.
In the invention, the heating temperature is preferably 95-100 ℃, and more preferably 98-100 ℃. The mass ratio of the sophora japonica to the sophora japonica is preferably (0.5-1): (0.5 to 1), more preferably 0.8 to 1:0.8 to 1. The source of the sophora flower and the sophora flower bud is not specially limited, and the sophora flower bud which are well known in the field can be used.
In the present invention, the mass ratio of the mixture to water is preferably 1: (10-12), more preferably 1: 12. The time for each extraction is preferably 1.5 h.
In the present invention, the plant extract is preferably concentrated and dried to obtain a powdered plant extract. The method of concentration is not particularly limited in the present invention, and a concentration method known in the art, such as a rotary evaporation method or a water bath concentration method, may be used. The method of drying is not particularly limited in the present invention, and a drying method known in the art, such as a vacuum drying method, may be used. In the embodiment of the invention, an orthogonal experiment is carried out by taking the feed-liquid ratio, the extraction times and the extraction time as three factors, and the result shows that the extraction times have more influence on the paste yield relative to the extraction time, and the feed-liquid ratio and the paste yield are in positive correlation.
In the present invention, the active ingredients in the extracted plant extract are quantitatively detected. The active ingredients in the powdered plant extract preferably include total flavonoids and polysaccharides. The mass percentage of the total flavone is 32-43%. The mass percentage of the polysaccharide is 3.3% -4.1%.
The invention provides a product with a function of reducing uric acid, which comprises the following components in parts by mass: 90-110 parts of plant extract, 70-90 parts of flavoring agent, 15-25 parts of adhesive and 1.8-2.3 parts of lubricant.
In the present invention, the product comprises a plant extract. The plant extract is preferably 100 parts by mass, and exerts a main blood uric acid lowering function as a functional active ingredient.
In the present invention, the product comprises a flavouring agent. The flavoring agent is preferably 80 parts by mass. The invention is not particularly limited in the kind of the flavoring agent, and a flavoring agent well known in the art, such as xylitol, may be used.
In the present invention, the product comprises an adhesive. The binder is preferably 20 parts by mass. The present invention is not particularly limited in kind of the binder, and it is sufficient to use a binder well known in the art, for example, starch (corn starch). The adhesive functions to bond and fill the sheet.
In the present invention, the product includes a lubricant. The lubricant is preferably 2 parts by mass. The type of lubricant used in the present invention is not particularly limited, and any lubricant known in the art, such as magnesium stearate, may be used. The lubricant acts as an intestinal lubricant.
In the present invention, the preparation method of the product is preferably as follows: mixing the above materials, adding into solvent, making into soft mass, tabletting, and oven drying to obtain granule. The solvent is preferably 95% aqueous ethanol. The soft material is preferably in a 'holding, conglobating, pressing and scattering' state. The compressed tablets are preferably passed through a 14 mesh sieve to obtain undersize granules. The drying temperature is preferably 60-70 ℃, and more preferably 65 ℃. The dried granules are preferably sieved by an 18-mesh sieve to obtain qualified granules. The product prepared by the method has the following characteristics: the degree of disintegration: within 30 minutes; friability: 0.48 percent; tabletting by a tabletting machine: the specification is 0.4 g/tablet. The prepared product is taken by healthy volunteers, and the result shows that over 66 percent of the patients have the blood uric acid content reduced, wherein over half of the patients have the blood uric acid content obviously reduced. The plant extract and the product prepared from the plant extract have the effect of reducing the content of uric acid. Thus, the product can be used to ameliorate gout symptoms and even to treat hyperuricemia.
In view of the function of reducing uric acid of the plant extract, the invention provides the application of the plant extract in preparing health care products for relieving ventilation or medicines for treating hyperuricemia.
In the invention, the taking method of the health care product or the medicine is preferably 0.5g of plant extract per time, and 1-2 times per day.
The plant extract with uric acid lowering function and the products and applications thereof provided by the present invention will be described in detail with reference to the following examples, which should not be construed as limiting the scope of the present invention.
Example 1
Preparation method of flos Sophorae Immaturus and flos Sophorae Immaturus extract
Mixing sophora flower decoction pieces and sophora flower bud decoction pieces according to a mass ratio of 1:1, taking 100g of decoction piece mixture, putting the decoction piece mixture into a 3L round-bottom flask, adding deionized water with the mass volume of A times, heating until boiling begins and timing C hours, filtering a liquid medicine No. 6 sieve (100 meshes), collecting filtrate, continuously adding water with the mass of A times to carry out boiling extraction, boiling and extracting for B times, combining the filtrates, concentrating to 500mL, taking 50mL, placing in a water bath at 80 ℃ to concentrate into paste, transferring to a vacuum drying oven to carry out drying (the vacuum drying oven is set at 80 ℃) to obtain mixed extract powder, and calculating the paste yield according to a formula I.
(mass of extract powder/total mass of decoction pieces) × 100% formula I
The results of the experiment are shown in table 1.
TABLE 1 orthogonal experimental table for extraction process yield
As can be seen from Table 1, the ratio of the feed to the liquid, the number of times of extraction and the time of extraction all affected the extraction yield of the extract. Compared with the extraction time, the extraction frequency has larger influence effect on the paste yield, and the paste yield is higher when the feed-liquid ratio and the extraction frequency are larger. The ratio of material to liquid is 8-12, the extraction times are 2-3 times, and the cream yield reaches more than 40% when the extraction time is 1-2 hours, wherein the ratio of material to liquid is 12, the extraction times are 3 times, and the cream yield is the highest when the extraction time is 2 hours and reaches more than 50%.
Example 2
Determination of total flavone content in plant extract
The determination method is specifically completed by referring to an ultraviolet spectroscopic detection method of total flavonoids in sophora japonica in 2020 edition pharmacopoeia, and specifically comprises the following steps:
1. preparation of control solutions
Taking 10mg of rutin reference substance, precisely weighing, placing in a 25mL measuring flask, adding appropriate amount of methanol, placing on a water bath, slightly heating to dissolve, cooling, adding methanol to scale, and shaking.
2. Preparation of the Standard Curve
Precisely measuring reference substance solutions 0.1mL, 0.5mL, 1mL, 1.5mL, 2mL, 2.5mL and 3mL in 25mL measuring flasks respectively, adding water to 5.0mL, adding 5% sodium nitrite solution 1mL, mixing, standing for 6 minutes, adding 10% aluminum nitrate solution 1mL, shaking, standing for 6 minutes, adding sodium hydroxide test solution 10mL (4%) and water to the scale, shaking, standing for 15 minutes, and measuring absorbance at the wavelength of 500nm by using an ultraviolet-visible spectrophotometry (general rule 0401) with corresponding reagents as blank. A standard curve was plotted with the concentration (c) as the abscissa and the absorbance (a) as the ordinate, and the regression equation was found to be a ═ 9.3011c +0.0006(r ═ 0.9998, n ═ 7).
The results of the experiment are shown in table 2.
TABLE 2 flavone Standard Curve data sheet
3. Preparation of test solution
0.05g of the dried powder sample in example 1 was taken and placed in a 50mL measuring flask, and methanol was added to the scale, and the mixture was shaken up to prepare a stock solution of the sample.
Precisely measuring 2mL of a test solution, placing in a 25mL measuring flask, adding water to 5mL, adding 1mL of 5% sodium nitrite solution, shaking up, and standing for 6 min; adding 1ml of 10% aluminum nitrate solution, shaking up, and standing for 6 min; adding 10ml of sodium hydroxide test solution, adding water to scale, shaking, standing for 15min, immediately measuring absorbance at 500nm wavelength by ultraviolet-visible spectrophotometry with corresponding reagent as blank. And reading the content of rutin in the test solution from the standard curve, and calculating to obtain the test solution.
The results of the experiment are shown in table 3:
TABLE 3 flavone content results table
From the results in table 3, it can be seen that the change trend of the flavone content in the extracts prepared by different preparation processes in example 1 is more consistent with the content change trend of the cream yield, the material-liquid ratio is 8-12, the extraction times are 2-3 times, the flavone content is up to 32% or more when the extraction time is 1-2 hours, and the expected material-liquid ratio is 12, the extraction times are 3 times, and the flavone content is highest when the extraction time is 2 hours.
Example 3
Determination of polysaccharide content in plant extracts
The polysaccharide determination is carried out by referring to an ultraviolet spectroscopic detection method of ganoderan in the pharmacopoeia of 2020 edition.
1. Taking 12mg of an anhydrous glucose reference substance, precisely weighing, putting into a 100mL measuring flask, adding a proper amount of deionized water for dissolving, shaking up, adding deionized water to the scale, and shaking up. And (4) putting the mixture into a 100mL measuring flask to obtain the glucose-glucose mixed solution (each 1 mL).
2. Preparation of the Standard Curve
Accurately weighing control solution 0.1mL, 0.4mL, 0.6mL, 1.0mL, 1.5mL, and 2mL, respectively placing in 10mL test tube with plug, respectively adding deionized water to 2.0mL, quickly and accurately adding 6mL sulfuric acid in ketone solution (accurately weighing anthraketone 0.1g, adding sulfuric acid 100mL to dissolve, shaking, immediately shaking, standing for 15min, immediately cooling in 4 deg.C refrigerator for 15min, taking out, taking corresponding reagent as blank, irradiating with ultraviolet-visible spectrophotometry, measuring absorbance at 625nm wavelength, taking concentration (c) as abscissa and absorbance (A) as ordinate, and drawing standard curve to obtain regression equation A of 41.678c-0.0212(r of 0.9964, n of 356).
The results of the experiment are shown in table 4:
TABLE 4 polysaccharide standard curve measured results table
3. Preparation of test solution
Accurately weighing 0.5g of sample to be detected, dissolving with 1mL of deionized water, slowly dropwise adding 7.5mL of absolute ethyl alcohol while stirring, shaking up, and standing at 4 ℃ for 12 h. Centrifuging, removing supernatant, dissolving precipitate with hot water, transferring to 50mL measuring flask, cooling, adding water to scale, and shaking; taking a proper amount of the solution, centrifuging, precisely measuring 1mL of the supernatant, putting the supernatant into a 25mL measuring flask, adding water to the scale, and shaking up to obtain the composition.
Assay method
Precisely measuring sample solution 2mL, placing in 10mL test tube with plug, performing the same method according to standard curve preparation method from the point of rapidly and precisely adding anthrapyridone sulfate solution 6mL, measuring absorbance, reading anhydrous glucose content in sample solution from standard curve, and calculating. The results of the experiment are shown in Table 5.
TABLE 5 measurement of polysaccharide content in plant extracts prepared by different preparation methods
As can be seen from table 5, the polysaccharide content of the extracted plant extract generally increases with the increase of the feed-water ratio and the extraction frequency, but the extension of the extraction time is not favorable for the extraction of the polysaccharide. The polysaccharide content in the plant extract prepared by the extraction process protected by the invention reaches more than 3.8 percent.
Example 4
By combining the data analysis of the above tables 1, 3 and 5 and considering the industrial mass production situation, the ratio of the material to the liquid is 12 times, the extraction is carried out for 2 times, the boiling extraction process is carried out for 2 hours each time to extract the decoction pieces, the extraction rate (table 6), the total flavone content (table 7) and the polysaccharide content (table 8) are respectively verified repeatedly for 3 times, and the experimental results are as follows.
TABLE 6 verification table for extraction process yield
TABLE 7 verification of total flavone content in extraction process
Remarking: wherein the average value of the ratio is: 40.57 percent, SD value 0.0169 and RSD value 4.17 percent, all reach the extraction requirements of the pharmacopoeia verification process.
TABLE 8 verification of polysaccharide content in extraction process
Remarking: wherein the average value of the ratio is: 3.57 percent, SD value 0.0071 and RSD value 4.80 percent, which all meet the extraction requirements of the pharmacopoeia verification process.
Example 5
Pulverizing the extract, sieving with a 50-mesh sieve, mixing 100g of the sieved extract with 80g of xylitol, 20g of starch and 2.0g of magnesium stearate, mixing, adding a proper amount of 95% ethanol to prepare a soft material until the soft material is in a 'holding agglomeration, pressing and scattering' state, grinding the soft material on a 14-mesh sieve to obtain uniform granules, placing the granules in a 65-DEG C oven, drying the granules, sieving with a 18-mesh sieve, and taking intermediate granules to obtain qualified granules (Qingfeng Ding Hua tablets).
The degree of disintegration: within 30 minutes;
friability: 0.48 percent;
tabletting specification of the tabletting machine: 0.4 g/tablet.
9 healthy males were recruited as volunteers, and each person took Qingfeng Dinghua tablets (containing 5.0g of flos Sophorae extract) on an empty stomach and 1 hour later, and blood uric acid value was detected by a commercially available blood uric acid instrument. The results are shown in Table 9.
TABLE 9 functional test results of Qingfeng Dingpian uric acid lowering
Note: the unit of blood uric acid is mu mol/L; < 181: the detection limit of the uric acid instrument is 181 mu mol/L, and <181 indicates that the blood uric acid value is lower than 181 mu mol/L.
A total of 9 male volunteers participated in the uric acid reducing function test of the Qingfeng Dihua flower tablet. The results show that the blood uric acid value of 6 people is reduced after taking the Qingfeng fixed tablet, wherein the blood uric acid value of 3 people is obviously reduced; the blood uric acid value of 2 persons is slightly increased, and the blood uric acid value of 1 person is obviously increased. The sophora flower slices for clearing wind and determining have a certain effect of reducing uric acid.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (10)
1. A plant extract with the function of reducing uric acid is characterized by being prepared by the following steps:
extracting the mixture of sophora flower and sophora flower bud by a water extraction heating reflux extraction method to obtain a plant extract;
the mass ratio of the mixture to water is 1: (8-12);
the extraction times are 2-3 times; the time for each extraction is 1-2 h.
2. The plant extract according to claim 1, wherein the mass ratio of the mixture to the water is 1: (10-12); the time for each extraction was 1.5 h.
3. The plant extract according to claim 1, wherein the heating temperature is 95 to 100 ℃.
4. The plant extract as claimed in claim 1, wherein the mass ratio of sophora flower to sophora flower bud is (0.5-1): (0.5 to 1).
5. The plant extract according to any one of claims 1 to 4, wherein the plant extract is concentrated and dried to obtain a powdery plant extract.
6. The plant extract as claimed in claim 5, wherein the active ingredients in the powdered plant extract comprise total flavonoids and polysaccharides;
the mass percentage content of the total flavone is 32-43 percent;
the mass percentage of the polysaccharide is 3.3% -4.1%.
7. A product with a function of reducing uric acid is characterized by comprising the following components in parts by mass: 90 to 110 parts of the plant extract of any one of claims 1 to 6, 70 to 90 parts of a flavoring agent, 15 to 25 parts of a binder, and 1.8 to 2.3 parts of a lubricant.
8. The product with uric acid reducing function according to claim 7, characterized in that the plant extract comprises 100 parts of plant extract, 80 parts of flavoring agent, 20 parts of adhesive and 2 parts of lubricant.
9. The product with uric acid lowering function according to claim 7 or 8, characterized in that the flavoring agent comprises xylitol; the binder comprises starch; the lubricant comprises magnesium stearate.
10. Use of the plant extract of any one of claims 1 to 6 for the preparation of a health product for relieving ventilation or a medicament for treating hyperuricemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111552263.XA CN114129612A (en) | 2021-12-17 | 2021-12-17 | Plant extract with function of reducing uric acid, product prepared from plant extract and application of plant extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111552263.XA CN114129612A (en) | 2021-12-17 | 2021-12-17 | Plant extract with function of reducing uric acid, product prepared from plant extract and application of plant extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114129612A true CN114129612A (en) | 2022-03-04 |
Family
ID=80382823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111552263.XA Pending CN114129612A (en) | 2021-12-17 | 2021-12-17 | Plant extract with function of reducing uric acid, product prepared from plant extract and application of plant extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114129612A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115919927A (en) * | 2022-12-26 | 2023-04-07 | 兰州理工大学 | Traditional Chinese medicine composition and application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181345A (en) * | 2007-11-15 | 2008-05-21 | 南京大学 | Application of flos Sophora chromocor extract in the preparation of medicament for restrainting uric acid transporter URAT1 |
-
2021
- 2021-12-17 CN CN202111552263.XA patent/CN114129612A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181345A (en) * | 2007-11-15 | 2008-05-21 | 南京大学 | Application of flos Sophora chromocor extract in the preparation of medicament for restrainting uric acid transporter URAT1 |
Non-Patent Citations (2)
| Title |
|---|
| 张瑛毓等: "具有降尿酸功效的食品研究进展", 《中国食物与营养》 * |
| 韩玲玲等: "槐花醇提物对2型糖尿病合并高尿酸血症小鼠疗效研究", 《中药材》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115919927A (en) * | 2022-12-26 | 2023-04-07 | 兰州理工大学 | Traditional Chinese medicine composition and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106692297B (en) | Composition for assisting in reducing blood sugar and preparation method and application thereof | |
| CN103919920A (en) | Buccal tablet retaining original ecology of wolfberry fruits and preparation process thereof | |
| CN101422465A (en) | Use of ursolic acid and plant extract containing the same | |
| CN114129612A (en) | Plant extract with function of reducing uric acid, product prepared from plant extract and application of plant extract | |
| CN101199581B (en) | Chick-pea embryo and bean sprout valid part, preparing method and application thereof | |
| CN108771068A (en) | A kind of sugar-free seabuckthorn leaf beverage and preparation method thereof | |
| CN109730972B (en) | Prunus humilis calcium tablet and preparation method thereof | |
| CN101147586B (en) | Health-care food for improving sleep | |
| CN102423424B (en) | Pathogenic fire dispelling and inflammation eliminating composition, preparation method, and pharmaceutical preparation thereof | |
| CN103860638A (en) | Preparation method of sophora alopecuroide flavonoid composition and new medical application | |
| CN101496837A (en) | 'Relingqing' chewable tablet and preparation method thereof | |
| CN101856438B (en) | Medicinal composition for treating infant asthma and preparation method and use thereof | |
| CN103932000A (en) | Ganoderma lucidum spore chewable tablet combined with bifidus factor as well as preparation technology thereof | |
| CN104544047A (en) | Original orange-flavor buccal tablets prepared from sodium L-ascorbate, and preparation method of buccal tablets | |
| CN113952419B (en) | Pharmaceutical composition for chronic renal failure and preparation method and application thereof | |
| JP2670742B2 (en) | α-amylase inhibitor | |
| CN106975028A (en) | A kind of preparation method for the Chinese medicine preparation for treating gout | |
| CN105455120A (en) | Golden camellia tea assisted blood sugar lowering capsule | |
| CN107373484B (en) | Cranberry composition with anti-inflammatory effect and preparation method and application thereof | |
| CN105166926A (en) | Wild guava oral administration tablets capable of reducing blood sugar and resisting oxidation and preparation method of wild guava oral administration tablets | |
| CN105030910A (en) | Blood-glucose-reducing antioxidative granule based on wild guava fruit extract and preparation method thereof | |
| CN115998787A (en) | Dandelion extract, preparation method and application thereof and uric acid-reducing dandelion composition | |
| CN110585358B (en) | Application of sorghum bran total flavonoids in preventing and treating gout diseases | |
| CN108310119A (en) | A kind of Herba Cistanches chewable tablets and preparation method thereof | |
| Packirisamy et al. | Coccinia grandis Extract Exerts Antihyperglycemic Effect through its Antioxidant, α-Amylase and α-Glucosidase Inhibitory Activities: An in vitro Study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |